

Shaun G Goodman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1470050/publications.pdf>

Version: 2024-02-01

446
papers

36,918
citations

4370

86
h-index

3476

182
g-index

469
all docs

469
docs citations

469
times ranked

23280
citing authors

#	ARTICLE	IF	CITATIONS
1	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2018, 379, 2097-2107.	13.9	2,211
2	Predictors of Hospital Mortality in the Global Registry of Acute Coronary Events. <i>Archives of Internal Medicine</i> , 2003, 163, 2345.	4.3	1,856
3	Initial Invasive or Conservative Strategy for Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1395-1407.	13.9	1,508
4	A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease. <i>New England Journal of Medicine</i> , 1997, 337, 447-452.	13.9	1,397
5	A Validated Prediction Model for All Forms of Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 2727.	3.8	1,344
6	Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). <i>BMJ: British Medical Journal</i> , 2006, 333, 1091.	2.4	1,236
7	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2018, 392, 1519-1529.	6.3	1,179
8	Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2011, 365, 699-708.	13.9	918
9	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2019, 380, 1509-1524.	13.9	833
10	Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. <i>New England Journal of Medicine</i> , 2012, 367, 1297-1309.	13.9	765
11	Decline in Rates of Death and Heart Failure in Acute Coronary Syndromes, 1999-2006. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1892.	3.8	744
12	Enoxaparin vs Unfractionated Heparin in High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Managed With an Intended Early Invasive Strategy. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 45-54.	3.8	702
13	Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. <i>New England Journal of Medicine</i> , 2017, 376, 1933-1942.	13.9	593
14	Intravenous Platelet Blockade with Cangrelor during PCI. <i>New England Journal of Medicine</i> , 2009, 361, 2330-2341.	13.9	560
15	Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction. <i>New England Journal of Medicine</i> , 2014, 371, 1016-1027.	13.9	538
16	Platelet Inhibition with Cangrelor in Patients Undergoing PCI. <i>New England Journal of Medicine</i> , 2009, 361, 2318-2329.	13.9	533
17	Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). <i>Lancet, The</i> , 2002, 359, 373-377.	6.3	496
18	Routine Early Angioplasty after Fibrinolysis for Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2009, 360, 2705-2718.	13.9	483

#	ARTICLE	IF	CITATIONS
19	Acute Coronary Syndromes Without Chest Pain, An Underdiagnosed and Undertreated High-Risk Group. <i>Chest</i> , 2004, 126, 461-469.	0.4	439
20	Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome. <i>Circulation</i> , 2009, 119, 2877-2885.	1.6	428
21	Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. <i>Circulation</i> , 2019, 140, 1693-1702.	1.6	371
22	Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial. <i>American Heart Journal</i> , 2014, 168, 682-689.e1.	1.2	365
23	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 133-144.	1.2	296
24	Efficacy and Bleeding Complications Among Patients Randomized to Enoxaparin or Unfractionated Heparin for Antithrombin Therapy in Non-ST-Segment Elevation Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 89-96.	3.8	278
25	Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (the GRACE registry). <i>American Journal of Cardiology</i> , 2002, 89, 791-796.	0.7	271
26	Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 761.	3.8	257
27	Association of Temporal Trends in Risk Factors and Treatment Uptake With Coronary Heart Disease Mortality, 1994-2005. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1841.	3.8	253
28	Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. <i>European Heart Journal</i> , 2008, 29, 609-617.	1.0	233
29	Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. <i>European Heart Journal</i> , 2007, 28, 1072-1078.	1.0	226
30	From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes The Global Registry of Acute Coronary Events (GRACE). <i>European Heart Journal</i> , 2003, 24, 1414-1424.	1.0	225
31	Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. <i>New England Journal of Medicine</i> , 2017, 376, 2032-2042.	13.9	225
32	Does Comorbidity Account for the Excess Mortality in Patients With Major Bleeding in Acute Myocardial Infarction?. <i>Circulation</i> , 2007, 116, 2793-2801.	1.6	213
33	Factors Associated With Major Bleeding Events. <i>Journal of the American College of Cardiology</i> , 2014, 63, 891-900.	1.2	212
34	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2018, 138, 527-536.	1.6	211
35	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 618-628.	5.5	207
36	Randomized Evaluation of the Safety and Efficacy of Enoxaparin Versus Unfractionated Heparin in High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Receiving the Glycoprotein IIb/IIIa Inhibitor Eptifibatide. <i>Circulation</i> , 2003, 107, 238-244.	1.6	200

#	ARTICLE	IF	CITATIONS
37	Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1785.	3.8	200
38	Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. <i>American Journal of Medicine</i> , 2004, 117, 73-81.	0.6	198
39	Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. <i>American Heart Journal</i> , 2003, 146, 33-41.	1.2	181
40	Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor. <i>Circulation</i> , 2012, 125, 978-986.	1.6	176
41	Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. <i>European Heart Journal</i> , 2007, 28, 2077-2086.	1.0	172
42	Bridging the gender gap: Insights from a contemporary analysis of sex-related differences in the treatment and outcomes of patients with acute coronary syndromes. <i>American Heart Journal</i> , 2012, 163, 66-73.	1.2	168
43	Factors influencing underutilization of evidence-based therapies in women. <i>European Heart Journal</i> , 2011, 32, 1337-1344.	1.0	166
44	Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (The Global Registry of Acute Coronary Events [GRACE]). <i>American Journal of Cardiology</i> , 2004, 93, 288-293.	0.7	165
45	The expanded Global Registry of Acute Coronary Events: Baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes. <i>American Heart Journal</i> , 2009, 158, 193-201.e5.	1.2	165
46	Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis. <i>European Heart Journal</i> , 2010, 31, 2156-2169.	1.0	165
47	Validation of the Global Registry of Acute Coronary Event (GRACE) risk score for in-hospital mortality in patients with acute coronary syndrome in Canada. <i>American Heart Journal</i> , 2009, 158, 392-399.	1.2	160
48	Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease—A list of participating ESSENCE Study Group investigators may be found in <i>N Engl J Med</i> 1997;337:447-52. <i>Journal of the American College of Cardiology</i> , 2000, 36, 693-698.	1.2	154
49	Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1167-1176.	1.2	154
50	Contemporary Management of Dyslipidemia in High-Risk Patients: Targets Still Not Met. <i>American Journal of Medicine</i> , 2006, 119, 676-683.	0.6	148
51	Management Patterns in Relation to Risk Stratification Among Patients With Non-ST Elevation Acute Coronary Syndromes. <i>Archives of Internal Medicine</i> , 2007, 167, 1009.	4.3	147
52	Safety and Tolerability of Atopaxar in the Treatment of Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2011, 123, 1843-1853.	1.6	147
53	Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb11 Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network (PARAGON-A); Global Use of Strategies To Open occluded arteries in acute coronary syndromes (GUSTO-IIb). <i>Journal of the American College of Cardiology</i> , 2001, 38, 64-71.	1.2	145
54	Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Chest</i> , 2008, 133, 670S-707S.	0.4	145

#	ARTICLE	IF	CITATIONS
55	Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. <i>European Heart Journal</i> , 2014, 35, 1873-1880.	1.0	145
56	Optimal medical therapy at discharge in patients with acute coronary syndromes: Temporal changes, characteristics, and 1-year outcome. <i>American Heart Journal</i> , 2007, 154, 1108-1115.	1.2	141
57	Clopidogrel Pharmacogenetics. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007811.	1.4	139
58	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events. <i>Journal of the American College of Cardiology</i> , 2019, 73, 387-396.	1.2	131
59	Elderly Patients With Acute Coronary Syndromes Managed Without Revascularization. <i>Circulation</i> , 2013, 128, 823-833.	1.6	130
60	Does Simplicity Compromise Accuracy in ACS Risk Prediction? A Retrospective Analysis of the TIMI and GRACE Risk Scores. <i>PLoS ONE</i> , 2009, 4, e7947.	1.1	123
61	Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?. <i>European Heart Journal</i> , 2007, 28, 1717-1722.	1.0	121
62	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2021, 143, 583-596.	1.6	119
63	Clinical trials evaluating red blood cell transfusion thresholds: An updated systematic review and with additional focus on patients with cardiovascular disease. <i>American Heart Journal</i> , 2018, 200, 96-101.	1.2	117
64	Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2020, 41, 4245-4255.	1.0	117
65	Aborted myocardial infarction in patients with ST-segment elevation. <i>Journal of the American College of Cardiology</i> , 2004, 44, 38-43.	1.2	110
66	Acute ST-Segment Elevation Myocardial Infarction. <i>Chest</i> , 2008, 133, 708S-775S.	0.4	110
67	In-Hospital Revascularization and One-Year Outcome of Acute Coronary Syndrome Patients Stratified by the GRACE Risk Score. <i>American Journal of Cardiology</i> , 2005, 96, 913-916.	0.7	108
68	Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. <i>European Heart Journal</i> , 2008, 30, 321-329.	1.0	108
69	Unprotected left main revascularization in patients with acute coronary syndromes. <i>European Heart Journal</i> , 2009, 30, 2308-2317.	1.0	108
70	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. <i>Circulation</i> , 2019, 140, 103-112.	1.6	107
71	Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 69, 73-83.	0.7	106
72	Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 418-435.	5.5	105

#	ARTICLE	IF	CITATIONS
73	Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , 2003, 146, 999-1006.	1.2	104
74	Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome. <i>Circulation</i> , 2020, 141, 1608-1617.	1.6	104
75	G-Protein-Coupled Receptors as Signaling Targets for Antiplatelet Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 449-457.	1.1	102
76	Time to Treatment Influences the Impact of ST-Segment Resolution on One-Year Prognosis. <i>Circulation</i> , 2001, 104, 2653-2659.	1.6	101
77	Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: Insights from the Canadian Acute Coronary Syndrome Registries. <i>American Heart Journal</i> , 2005, 150, 690-694.	1.2	101
78	The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: Lessons from the Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , 2006, 151, 654-660.	1.2	101
79	Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2019, 4, 273.	3.0	100
80	Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. <i>American Journal of Cardiology</i> , 1998, 82, 19L-24L.	0.7	98
81	Cardiogenic shock complicating acute coronary syndromes: Insights from the Global Registry of Acute Coronary Events. <i>American Heart Journal</i> , 2012, 163, 963-971.	1.2	98
82	Age-related differences in the management and outcome of patients with acute coronary syndromes. <i>American Heart Journal</i> , 2006, 151, 352-359.	1.2	94
83	Relationship of ST elevation in lead aVR with angiographic findings and outcome in non-ST elevation acute coronary syndromes. <i>American Heart Journal</i> , 2007, 154, 71-78.	1.2	93
84	Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 739-750.	1.1	90
85	Elevated leukocyte count and adverse hospital events in patients with acute coronary syndromes: findings from the Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , 2004, 147, 42-48.	1.2	89
86	Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada. <i>Canadian Journal of Cardiology</i> , 2010, 26, 297-302.	0.8	89
87	One-year outcome of patients after acute coronary syndromes (from the Canadian Acute Coronary) $T_j ETQq1 1 0.784314 rgBT/Overlacc$	0.7	88
88	Clinical trial-derived risk model may not generalize to real-world patients with acute coronary syndrome. <i>American Heart Journal</i> , 2004, 148, 1020-1027.	1.2	84
89	Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction. <i>European Heart Journal</i> , 2009, 30, 549-557.	1.0	84
90	Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 141, 1618-1627.	1.6	84

#	ARTICLE	IF	CITATIONS
91	Inhibition of delta-protein kinase C by delcasetib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. <i>European Heart Journal</i> , 2014, 35, 2516-2523.	1.0	83
92	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	83
93	Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. <i>Circulation</i> , 2019, 140, 2054-2062.	1.6	83
94	Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. <i>European Heart Journal</i> , 2014, 35, 233-241.	1.0	81
95	Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up. <i>American Journal of Medicine</i> , 2015, 128, 766-775.	0.6	81
96	Association of Clinical Factors and Therapeutic Strategies With Improvements in Survival Following Non- σ ST-Elevation Myocardial Infarction, 2003-2013. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1073.	3.8	80
97	Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. <i>Circulation</i> , 2020, 141, 781-783.	1.6	80
98	A Subgroup Analysis of the Impact of Prerandomization Antithrombin Therapy on Outcomes in the SYNERGY Trial. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1346-1354.	1.2	79
99	Rationale and design of Enhanced Angiogenic Cell Therapy in Acute Myocardial Infarction (ENACT-AMI): The first randomized placebo-controlled trial of enhanced progenitor cell therapy for acute myocardial infarction. <i>American Heart Journal</i> , 2010, 159, 354-360.	1.2	77
100	Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. <i>Circulation</i> , 2021, 144, 1295-1307.	1.6	75
101	Non- σ Q-Wave Versus Q-Wave Myocardial Infarction After Thrombolytic Therapy. <i>Circulation</i> , 1998, 97, 444-450.	1.6	72
102	Late assessment of thrombolytic efficacy (LATE) study: Prognosis in patients with non-Q wave myocardial infarction. <i>Journal of the American College of Cardiology</i> , 1996, 27, 1327-1332.	1.2	71
103	Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies. <i>European Heart Journal</i> , 2020, 41, 86-94.	1.0	71
104	An open-Label, 2 \times 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. <i>American Heart Journal</i> , 2018, 200, 17-23.	1.2	69
105	Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 580-589.	3.3	68
106	In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 499-508.	0.4	68
107	Influence of Age on Use of Cardiac Catheterization and Associated Outcomes in Patients With Non-ST-Elevation Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2009, 103, 1530-1536.	0.7	67
108	Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction. <i>JAMA Cardiology</i> , 2018, 3, 391.	3.0	65

#	ARTICLE	IF	CITATIONS
109	Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 39.	3.8	65
110	Applying the Evidence. <i>Stroke</i> , 2009, 40, 1417-1424.	1.0	64
111	Optimal Medical Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 530-537.	0.9	64
112	Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2819-2828.	1.2	64
113	Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The Global Registry of Acute Coronary Events. <i>European Heart Journal</i> , 2010, 31, 667-675.	1.0	63
114	Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. <i>Diabetes Care</i> , 2020, 43, 446-452.	4.3	63
115	Guideline-indicated treatments and diagnostics, GRACE risk score, and survival for non-ST elevation myocardial infarction. <i>European Heart Journal</i> , 2018, 39, 3798-3806.	1.0	62
116	High-grade atrioventricular block in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events. <i>European Heart Journal</i> , 2015, 36, 976-983.	1.0	61
117	Frailty and Outcomes After Myocardial Infarction: Insights From the CONCORDANCE Registry. <i>Journal of the American Heart Association</i> , 2018, 7, e009859.	1.6	60
118	Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. <i>American Heart Journal</i> , 2021, 231, 121-127.	1.2	60
119	Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy. <i>Journal of the American College of Cardiology</i> , 2000, 36, 1507-1513.	1.2	59
120	The 12-lead electrocardiogram as a predictive tool of mortality after acute myocardial infarction: Current status in an era of revascularization and reperfusion. <i>American Heart Journal</i> , 2006, 152, 11-18.	1.2	59
121	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. <i>Journal of the American College of Cardiology</i> , 2021, 78, 421-433.	1.2	58
122	High-Risk Patients With Acute Coronary Syndromes Treated With Low-Molecular-Weight or Unfractionated Heparin. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 2594.	3.8	57
123	Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 140, 1921-1932.	1.6	57
124	Spontaneous reperfusion in ST-elevation myocardial infarction: Comparison of angiographic and electrocardiographic assessments. <i>American Heart Journal</i> , 2008, 156, 248-255.	1.2	56
125	Temporal Trends of Women Enrollment in Major Cardiovascular Randomized Clinical Trials. <i>Canadian Journal of Cardiology</i> , 2019, 35, 653-660.	0.8	56
126	Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?. <i>American Heart Journal</i> , 2000, 139, 423-429.	1.2	55

#	ARTICLE	IF	CITATIONS
127	Cost-Effectiveness of Specialized Multidisciplinary Heart Failure Clinics in Ontario, Canada. <i>Value in Health</i> , 2010, 13, 915-921.	0.1	55
128	Risk Stratification in the Setting of Non-ST Elevation Acute Coronary Syndromes 1999-2007. <i>American Journal of Cardiology</i> , 2011, 108, 617-624.	0.7	53
129	Outcomes of Women and Men With Acute Coronary Syndrome Treated With and Without Percutaneous Coronary Revascularization. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	52
130	Delay to reperfusion in patients with acute myocardial infarction presenting to acute care hospitals: an international perspective. <i>European Heart Journal</i> , 2010, 31, 1328-1336.	1.0	51
131	Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. <i>European Heart Journal</i> , 2020, 41, 2248-2258.	1.0	51
132	Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 162-171.	1.2	50
133	Canada Acute Coronary Syndrome Risk Score: A new risk score for early prognostication in acute coronary syndromes. <i>American Heart Journal</i> , 2013, 166, 58-63.	1.2	49
134	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1177-1186.	1.2	49
135	Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2297-2308.	1.2	48
136	Thrombolysis and Q Wave Versus Non-Q Wave First Acute Myocardial Infarction: A GUSTO-I Substudy. <i>Journal of the American College of Cardiology</i> , 1997, 29, 770-777.	1.2	47
137	Time to Coronary Angiography and Outcomes Among Patients With High-Risk Non-â€œST-Segmentâ€œ Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2007, 116, 2669-2677.	1.6	47
138	Prevalence of dyslipidemia in statin-treated patients in Canada: Results of the DYSlipidemia International Study (DYSIS). <i>Canadian Journal of Cardiology</i> , 2010, 26, e330-e335.	0.8	46
139	Dual Antiplatelet Therapy Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG. <i>Journal of the American College of Cardiology</i> , 2017, 69, 119-127.	1.2	46
140	Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol. <i>Circulation</i> , 2021, 143, 1109-1122.	1.6	46
141	Unraveling the spectrum of left bundle branch block in acute myocardial infarction: Insights from the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT 2 and 3) trials. <i>American Heart Journal</i> , 2006, 151, 10-15.	1.2	45
142	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2019, 40, 2801-2809.	1.0	45
143	Prediction of One-Year Survival in High-Risk Patients with Acute Coronary Syndromes: Results from the SYNERGY Trial. <i>Journal of General Internal Medicine</i> , 2008, 23, 310-316.	1.3	44
144	Obesity in patients with non-ST-segment elevation acute coronary syndromes: Results from the SYNERGY trial. <i>International Journal of Cardiology</i> , 2010, 139, 123-133.	0.8	44

#	ARTICLE	IF	CITATIONS
145	Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial. <i>European Heart Journal</i> , 2015, 36, 385-392.	1.0	44
146	Underuse of evidence-based treatment partly explains the worse clinical outcome in diabetic patients with acute coronary syndromes. <i>American Heart Journal</i> , 2006, 152, 676-683.	1.2	43
147	Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial infarction to open the Coronary artery (ATLANTIC) study. <i>American Heart Journal</i> , 2013, 165, 515-522.	1.2	43
148	Paradoxical use of invasive cardiac procedures for patients with non-ST segment elevation myocardial infarction: An international perspective from the CRUSADE Initiative and the Canadian ACS Registries I and II. <i>Canadian Journal of Cardiology</i> , 2007, 23, 1073-1079.	0.8	41
149	Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. <i>European Heart Journal</i> , 2011, 32, 2256-2265.	1.0	41
150	Rationale and design of the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). <i>American Heart Journal</i> , 2008, 155, 19-25.	1.2	40
151	Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 2302-2309.e6.	0.4	40
152	Relationship Between Time to Invasive Assessment and Clinical Outcomes of Patients Undergoing an Early Invasive Strategy After Fibrinolysis for ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 166-174.	1.1	39
153	Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2015, 66, 777-787.	1.2	39
154	Is There a Sex Gap in Surviving an Acute Coronary Syndrome or Subsequent Development of Heart Failure?. <i>Circulation</i> , 2020, 142, 2231-2239.	1.6	39
155	Secular trends in acute coronary syndrome hospitalization from 1994 to 2005. <i>Canadian Journal of Cardiology</i> , 2010, 26, 129-134.	0.8	38
156	High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. <i>American Heart Journal</i> , 2018, 202, 97-103.	1.2	38
157	Cardiovascular Risk Factors and In-hospital Mortality in Acute Coronary Syndromes: Insights From the Canadian Global Registry of Acute Coronary Events. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1455-1461.	0.8	37
158	Treatment and one-year outcome of patients with renal dysfunction across the broad spectrum of acute coronary syndromes. <i>Canadian Journal of Cardiology</i> , 2006, 22, 115-120.	0.8	35
159	Prognostic Significance of Admission Heart Failure in Patients With Non-ST-Elevation Acute Coronary Syndromes (from the Canadian Acute Coronary Syndrome Registries). <i>American Journal of Cardiology</i> , 2006, 98, 470-473.	0.7	35
160	Comparison of Baseline Characteristics, Management and Outcome of Patients With Non-ST-Segment Elevation Acute Coronary Syndrome in Versus Not in Clinical Trials. <i>American Journal of Cardiology</i> , 2010, 106, 1389-1396.	0.7	35
161	Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI. <i>American Heart Journal</i> , 2017, 192, 105-112.	1.2	35
162	Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. <i>European Heart Journal</i> , 2020, 41, 4114-4123.	1.0	35

#	ARTICLE	IF	CITATIONS
163	Relation Between Obesity and the Attainment of Optimal Blood Pressure and Lipid Targets in High Vascular Risk Outpatients. <i>American Journal of Cardiology</i> , 2010, 106, 1270-1276.	0.7	34
164	Relationship between risk stratification at admission and treatment effects of early invasive management following fibrinolysis: insights from the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). <i>European Heart Journal</i> , 2011, 32, 1994-2002.	1.0	34
165	Association of Anemia With Outcomes Among ST-Segmentâ€Elevation Myocardial Infarction Patients Receiving Primary Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e007175.	1.4	34
166	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. <i>Circulation</i> , 2019, 140, 1578-1589.	1.6	34
167	Relation Between Hemoglobin Level and Recurrent Myocardial Ischemia in Acute Coronary Syndromes Detected by Continuous Electrocardiographic Monitoring. <i>American Journal of Cardiology</i> , 2010, 106, 1417-1422.	0.7	33
168	Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 33-43.	0.8	33
169	Treatment of Reinfarction After Thrombolytic Therapy for Acute Myocardial Infarction. <i>Circulation</i> , 2001, 103, 954-960.	1.6	32
170	Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with nonâ€ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. <i>American Heart Journal</i> , 2006, 151, 373-379.	1.2	32
171	Temporal trends in the use of invasive cardiac procedures for non-ST segment elevation acute coronary syndromes according to initial risk stratification. <i>Canadian Journal of Cardiology</i> , 2009, 25, e370-e376.	0.8	32
172	Comparison of primary coronary angioplasty versus thrombolysis in patients with ST-segment elevation acute myocardial infarction and grade II and grade III myocardial ischemia on the enrollment electrocardiogram. <i>American Journal of Cardiology</i> , 2001, 88, 842-847.	0.7	31
173	Do clinical factors explain persistent sex disparities in the use of acute reperfusion therapy in STEMI in Sweden and Canada?. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2013, 2, 350-358.	0.4	31
174	Effect of Pre-Hospital Ticagrelor During the Firstâ24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 646-656.	1.1	31
175	Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy. <i>American Heart Journal</i> , 2000, 139, 962-970.	1.2	30
176	Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer. <i>JACC: CardioOncology</i> , 2020, 2, 70-81.	1.7	30
177	Objective Risk Assessment vs Standard Care for Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2021, 6, 304.	3.0	29
178	Management of risk in peripheral artery disease: Recent therapeutic advances. <i>American Heart Journal</i> , 2005, 150, 35-40.	1.2	28
179	Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes. <i>American Heart Journal</i> , 2009, 157, 642-650.e1.	1.2	28
180	Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: contribution of weighting the composite endpoint. <i>European Heart Journal</i> , 2013, 34, 903-908.	1.0	28

#	ARTICLE	IF	CITATIONS
181	ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction. <i>European Heart Journal</i> , 2003, 24, 1515-1522.	1.0	27
182	Adverse outcomes in fibrinolytic-based facilitated percutaneous coronary intervention: insights from the ASSENT-4 PCI electrocardiographic substudy. <i>European Heart Journal</i> , 2008, 29, 871-879.	1.0	27
183	Disparities in Management Patterns and Outcomes of Patients With Non-ST-Elevation Acute Coronary Syndrome With and Without a History of Cerebrovascular Disease. <i>American Journal of Cardiology</i> , 2010, 105, 1083-1089.	0.7	27
184	Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term risk, clinical management and healthcare Resource utilization of stable coronary artery disease (TIGRIS) observational study. <i>International Journal of Cardiology</i> , 2017, 236, 54-60.	0.8	27
185	Association between gender and short-term outcome in patients with ST elevation myocardial infarction participating in the international, prospective, randomised Administration of Ticagrelor in the catheterisation Laboratory or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) trial: a prespecified analysis. <i>BMJ Open</i> , 2017, 7, e015241.	0.8	27
186	Evaluation of the impact of the GRACE risk score on the management and outcome of patients hospitalised with non-ST elevation acute coronary syndrome in the UK: protocol of the UKGRIS cluster-randomised registry-based trial. <i>BMJ Open</i> , 2019, 9, e032165.	0.8	27
187	ST-segment depression in non-ST elevation acute coronary syndromes: Quantitative analysis may not provide incremental prognostic value beyond comprehensive risk stratification. <i>American Heart Journal</i> , 2006, 152, 270-276.	1.2	26
188	Increased Uptake of Guideline-Recommended Oral Antiplatelet Therapy: Insights from the Canadian Acute Coronary Syndrome Reflective. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1725-1731.	0.8	26
189	Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. <i>American Heart Journal</i> , 2015, 170, 683-694.e3.	1.2	26
190	Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis. <i>American Heart Journal</i> , 2017, 190, 135-139.	1.2	26
191	Living alone and cardiovascular disease outcomes. <i>Heart</i> , 2019, 105, 1087-1095.	1.2	26
192	Higher T-Wave Amplitude Associated With Better Prognosis in Patients Receiving Thrombolytic Therapy for Acute Myocardial Infarction (a GUSTO-I Substudy) 11This study was funded by grants from Bayer, New York, New York; CIBA-Corning, Medfield, Massachusetts; Genentech, South San Francisco, California; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.. <i>American Journal of Cardiology</i> , 1998, 81, 1078-1084.	0.7	25
193	Troponin is more useful than creatine kinase in predicting one-year mortality among acute coronary syndrome patients. <i>European Heart Journal</i> , 2004, 25, 2006-2012.	1.0	25
194	Missed opportunities for the secondary prevention of cardiovascular disease in Canada. <i>Canadian Journal of Cardiology</i> , 2007, 23, 1124-1130.	0.8	25
195	Diabetes for Cardiologists: Practical Issues in Diagnosis and Management. <i>Canadian Journal of Cardiology</i> , 2017, 33, 366-377.	0.8	25
196	Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey. <i>Canadian Journal of Diabetes</i> , 2018, 42, 130-137.	0.4	25
197	Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008018.	1.4	25
198	Discordance Between Physicians' Estimation of Patient Cardiovascular Risk and Use of Evidence-Based Medical Therapy. <i>American Journal of Cardiology</i> , 2008, 102, 1142-1145.	0.7	24

#	ARTICLE	IF	CITATIONS
199	Management patterns of non-ST segment elevation acute coronary syndromes in relation to prior coronary revascularization. <i>American Heart Journal</i> , 2010, 159, 40-46.	1.2	24
200	Development and prognosis of non-Q-wave myocardial infarction in the thrombolytic era. <i>American Heart Journal</i> , 2002, 144, 243-250.	1.2	24
201	Negative T waves shortly after ST-elevation acute myocardial infarction are a powerful marker for improved survival rate. <i>American Heart Journal</i> , 2000, 140, 385-394.	1.2	23
202	Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , 2007, 153, 960-969.	1.2	23
203	Comparison of Utilization of Statin Therapy at Hospital Discharge and Six-Month Outcomes in Patients With an Acute Coronary Syndrome and Serum Low-Density Lipoprotein ≥ 100 mg/dl Versus < 100 mg/dl. <i>American Journal of Cardiology</i> , 2007, 100, 913-918.	0.7	23
204	Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: Results from SYNERGY. <i>International Journal of Cardiology</i> , 2010, 144, 36-41.	0.8	23
205	Treatment and Outcomes of Patients With Suspected Acute Coronary Syndromes in Relation to Initial Diagnostic Impressions (Insights from the Canadian Global Registry of Acute Coronary Events [GRACE]) <i>Tj ETQq1 1,0,784314,rgBT/Ove</i> 202-207.	0.7	23
206	A cluster randomized trial of objective risk assessment versus standard care for acute coronary syndromes: Rationale and design of the Australian GRACE Risk score Intervention Study (AGRIS). <i>American Heart Journal</i> , 2015, 170, 995-1004.e1.	1.2	23
207	Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial. <i>American Heart Journal</i> , 2016, 182, 62-71.	1.2	23
208	Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 173-183.	1.0	23
209	Alirocumab after acute coronary syndrome in patients with a history of heart failure. <i>European Heart Journal</i> , 2022, 43, 1554-1565.	1.0	23
210	Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. <i>American Journal of Cardiology</i> , 1994, 74, 657-661.	0.7	22
211	Long-term prognostic value and therapeutic implications of continuous ST-segment monitoring in acute coronary syndrome. <i>American Heart Journal</i> , 2007, 153, 500-506.	1.2	22
212	Temporal trend of in-hospital major bleeding among patients with non ST-elevation acute coronary syndromes. <i>American Heart Journal</i> , 2010, 160, 420-427.	1.2	22
213	Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: Insights from the Global Registry of Acute Coronary Events. <i>American Heart Journal</i> , 2010, 160, 855-861.	1.2	22
214	Prognostic significance of presenting blood pressure in non-ST-segment elevation acute coronary syndrome in relation to prior history of hypertension. <i>American Heart Journal</i> , 2013, 166, 716-722.	1.2	22
215	ABCD-GENE Score and Clinical Outcomes Following Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial. <i>Journal of the American Heart Association</i> , 2022, 11, e024156.	1.6	22
216	Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an EXTRACT-TIMI 25 analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 11-17.	1.0	21

#	ARTICLE	IF	CITATIONS
217	Targeted Temperature Management Processes and Outcomes After Out-of-Hospital Cardiac Arrest. <i>Critical Care Medicine</i> , 2014, 42, 2565-2574.	0.4	21
218	Temporal Trends in Utilization of Cardiac Therapies and Outcomes for Myocardial Infarction by Degree of Chronic Kidney Disease: A Report From the NCDR Chest Pain MI Registry. <i>Journal of the American Heart Association</i> , 2018, 7, e010394.	1.6	21
219	QRS prolongation in patients with acute coronary syndromes. <i>American Heart Journal</i> , 2010, 159, 593-598.	1.2	20
220	Management and Outcome of Acute Coronary Syndrome Patients in Relation to Prior History of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2012, 28, 443-449.	0.8	20
221	Use and Timing of Coronary Angiography and Associated In-hospital Outcomes in Canadian Non-ST-Segment Elevation Myocardial Infarction Patients: Insights from the Canadian Global Registry of Acute Coronary Events. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1429-1435.	0.8	20
222	Comparative prognostic value of T-wave inversion and ST-segment depression on the admission electrocardiogram in non-ST-segment elevation acute coronary syndromes. <i>American Heart Journal</i> , 2013, 166, 290-297.	1.2	20
223	Prognostic significance of low QRS voltage on the admission electrocardiogram in acute coronary syndromes. <i>International Journal of Cardiology</i> , 2015, 190, 34-39.	0.8	20
224	Effectiveness of Interventions Aimed at Increasing Statin-Prescribing Rates in Primary Cardiovascular Disease Prevention. <i>JAMA Cardiology</i> , 2019, 4, 1160.	3.0	20
225	Meta-Analysis of Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin According to Time in Therapeutic Range in Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2021, 140, 62-68.	0.7	20
226	Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: Observations from the OPUS-TIMI 16 trial. <i>American Heart Journal</i> , 2005, 149, 275-283.	1.2	19
227	Electrocardiographic infarct size assessment after thrombolysis: Insights from the Acute Myocardial Infarction STudy Adenosine (AMISTAD) trial. <i>American Heart Journal</i> , 2005, 150, 659-665.	1.2	19
228	Long-term outcomes associated with hospital acquired thrombocytopenia among patients with non-ST-segment elevation acute coronary syndrome. <i>American Heart Journal</i> , 2014, 168, 189-196.e1.	1.2	19
229	Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudy. <i>American Heart Journal</i> , 2016, 180, 82-89.	1.2	19
230	GRACE risk score: Sex-based validity of in-hospital mortality prediction in Canadian patients with acute coronary syndrome. <i>International Journal of Cardiology</i> , 2017, 244, 24-29.	0.8	19
231	Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCel Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e009304.	1.6	19
232	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. <i>Diabetes Care</i> , 2021, 44, 1219-1227.	4.3	19
233	Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 330-340.	5.5	19
234	Prognostic value of dipyridamole SPECT imaging in low-risk patients after myocardial infarction. <i>Journal of Nuclear Cardiology</i> , 2001, 8, 136-143.	1.4	18

#	ARTICLE	IF	CITATIONS
235	Skin tissue cholesterol (SkinTc) is related to angiographically-defined cardiovascular disease. <i>Atherosclerosis</i> , 2003, 171, 255-258.	0.4	18
236	Transfer for urgent percutaneous coronary intervention early after thrombolysis for ST-elevation myocardial infarction: The TRANSFER-AMI pilot feasibility study. <i>Canadian Journal of Cardiology</i> , 2006, 22, 1121-1126.	0.8	18
237	Supporting a call to action for peripheral artery disease: Insights from two prospective clinical registries. <i>Journal of Vascular Surgery</i> , 2006, 44, 776-781.	0.6	18
238	Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non-“ST-elevation acute coronary syndrome patients: The Canadian Global Registry of Acute Coronary Events (GRACE) experience. <i>American Heart Journal</i> , 2009, 158, 917-924.	1.2	18
239	Identification and Management of Patients at Elevated Cardiometabolic Risk in Canadian Primary Care: How Well Are We Doing?. <i>Canadian Journal of Cardiology</i> , 2013, 29, 960-968.	0.8	18
240	Risk Stratification and Stroke Prevention Therapy Care Gaps in Canadian Atrial Fibrillation Patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients) <i>Tj ETQq0 0 OrgBT /Overlock 10 T</i>		
241	Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry. <i>Clinical Cardiology</i> , 2020, 43, 24-32.	0.7	18
242	Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trial. <i>EuroIntervention</i> , 2017, 13, 69-77.	1.4	18
243	Differences Between Local Hospital and Core Laboratory Interpretation of the Admission Electrocardiogram in Patients With Acute Coronary Syndromes and Their Relation to Outcome. <i>American Journal of Cardiology</i> , 2007, 100, 169-174.	0.7	17
244	Bleeding and outcome in acute coronary syndrome: Insights from continuous electrocardiogram monitoring in the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. <i>American Heart Journal</i> , 2008, 156, 769-775.	1.2	17
245	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005858.	0.9	17
246	Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC Trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 208-217.	0.4	17
247	Randomized comparison of T-type versus L-type calcium-channel blockade on exercise duration in stable angina: Results of the Posicor Reduction of Ischemia During Exercise (PRIDE) trial. <i>American Heart Journal</i> , 2002, 144, 60-67.	1.2	16
248	How does the prognosis of diabetes compare with that of established vascular disease? Insights from the Canadian Vascular Protection (VP) Registry. <i>American Heart Journal</i> , 2004, 148, 1028-1033.	1.2	16
249	Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 36-43.	1.0	16
250	Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (COAPT). <i>American Heart Journal</i> , 2016, 181, 26-34.	1.2	16
251	Use of proven therapies in non-“ST-elevation acute coronary syndromes according to evidence-based risk stratification. <i>American Heart Journal</i> , 2007, 153, 493-499.	1.2	15
252	The future of cardiovascular clinical research in North America and beyond-“addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. <i>American Heart Journal</i> , 2015, 169, 743-750.	1.2	15

#	ARTICLE	IF	CITATIONS
253	Clinical Characteristics, Management, and Outcomes of Acute Coronary Syndrome in Patients With Right Bundle Branch Block on Presentation. <i>American Journal of Cardiology</i> , 2016, 117, 754-759.	0.7	15
254	Spontaneous MI After Non- σ ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1289-1297.	1.2	15
255	The underutilisation of dual antiplatelet therapy in acute coronary syndrome. <i>International Journal of Cardiology</i> , 2017, 240, 30-36.	0.8	15
256	Utilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decade. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 66, 149-157.	0.7	14
257	Reperfusion Strategies and Outcomes of ST-Segment Elevation Myocardial Infarction Patients in Canada: Observations From the Global Registry of Acute Coronary Events (GRACE) and the Canadian Registry of Acute Coronary Events (CANRACE). <i>Canadian Journal of Cardiology</i> , 2012, 28, 40-47.	0.8	14
258	Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada. <i>ClinicoEconomics and Outcomes Research</i> , 2014, 6, 49.	0.7	14
259	The Risk Stratification and Stroke Prevention Therapy Care Gap in Canadian Atrial Fibrillation Patients. <i>Canadian Journal of Cardiology</i> , 2016, 32, 336-343.	0.8	14
260	Non-ST segment elevation acute coronary syndromes: A simplified risk-oriented algorithm. <i>Canadian Journal of Cardiology</i> , 2006, 22, 663-677.	0.8	13
261	Recurrent ischemia across the spectrum of acute coronary syndromes: Prevalence and prognostic significance of (Re-)infarction and ST-segment changes in a large contemporary registry. <i>International Journal of Cardiology</i> , 2010, 145, 15-20.	0.8	13
262	Temporal Patterns of Lipid Testing and Statin Therapy in Acute Coronary Syndrome Patients (from the Tj ETQq0 0 0 rgBT /Overlock 10 T	0.7	13
263	Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. <i>Heart</i> , 2015, 101, 1475-1484.	1.2	13
264	Prognostic value of dynamic electrocardiographic T wave changes in non-ST elevation acute coronary syndrome. <i>Heart</i> , 2016, 102, 1396-1402.	1.2	13
265	Alignment of site versus adjudication committee-based diagnosis with patient outcomes: Insights from the Providing Rapid Out of Hospital Acute Cardiovascular Treatment 3 trial. <i>Clinical Trials</i> , 2016, 13, 140-148.	0.7	13
266	Interprovincial Differences in Canadian Coronary Care Unit Resource Use and Outcomes. <i>Canadian Journal of Cardiology</i> , 2017, 33, 166-169.	0.8	13
267	Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial. <i>American Heart Journal</i> , 2018, 202, 89-96.	1.2	13
268	International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing. <i>Pharmacogenetics and Genomics</i> , 2019, 29, 76-83.	0.7	13
269	Lipid Testing, Lipid-Modifying Therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Eligibility in 27%979 Patients With Incident Acute Coronary Syndrome. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e006646.	0.9	13
270	Low-molecular-weight heparin compared with unfractionated heparin for patients with non- σ ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: Results from the CRUSADE initiative. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 21, 211-220.	1.0	12

#	ARTICLE	IF	CITATIONS
271	Achieving Quality Indicator Benchmarks and Potential Impact on Coronary Heart Disease Mortality. Canadian Journal of Cardiology, 2011, 27, 756-762.	0.8	12
272	Population-Based Study on Patterns of Cardiac Stress Testing After Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	12
273	Rationale and design of the long-term risk, clinical management, and healthcare Resource utilization of stable coronary artery disease in post-myocardial infarction patients (TIGRIS) study. Clinical Cardiology, 2017, 40, 1197-1204.	0.7	12
274	Use of clinical risk stratification in non-ST elevation acute coronary syndromes: an analysis from the CONCORDANCE registry. European Heart Journal Quality of Care & Clinical Outcomes, 2018, 4, 309-317.	1.8	12
275	Association between levosimendan, postoperative AKI, and mortality in cardiac surgery: Insights from the LEVO-CTS trial. American Heart Journal, 2021, 231, 18-24.	1.2	12
276	Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention. Journal of the American College of Cardiology, 2022, 79, 417-427.	1.2	12
277	A dynamic model forecasting myocardial infarct size before, during, and after reperfusion therapy: an ASSENT-2 ECG/VCG substudy. European Heart Journal, 2005, 26, 1726-1733.	1.0	11
278	The prognostic value of the admission and pre-discharge electrocardiogram in acute coronary syndromes: The GUSTO-IIb ECG Core Laboratory experience. American Heart Journal, 2006, 152, 277-284.	1.2	11
279	Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial. European Heart Journal, 2007, 28, 1079-1084.	1.0	11
280	Local hospital vs. core-laboratory interpretation of the admission electrocardiogram in acute coronary syndromes: increased mortality in patients with unrecognized ST-elevation myocardial infarction. European Heart Journal, 2007, 29, 31-37.	1.0	11
281	Usefulness of Quantitative Versus Qualitative ST-Segment Depression for Risk Stratification of Non-ST Elevation Acute Coronary Syndromes in Contemporary Clinical Practice. American Journal of Cardiology, 2008, 101, 919-924.	0.7	11
282	Predictors and Implications of Q-Waves in ST-Elevation Acute Coronary Syndromes. American Journal of Medicine, 2009, 122, 144-151.	0.6	11
283	Evaluation of left ventricular ejection fraction in non-ST-segment elevation acute coronary syndromes and its relationship to treatment. American Heart Journal, 2010, 159, 605-611.	1.2	11
284	Use of Clopidogrel Post-Coronary Artery Bypass Surgery in Canadian Patients With Acute Coronary Syndromes. Canadian Journal of Cardiology, 2011, 27, 711-715.	0.8	11
285	In-hospital management and outcomes of acute coronary syndromes in relation to prior history of heart failure. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 214-222.	0.4	11
286	Previous and New Onset Atrial Fibrillation and Associated Outcomes in Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events). American Journal of Cardiology, 2018, 122, 944-951.	0.7	11
287	Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial. Thrombosis and Haemostasis, 2020, 120, 065-074.	1.8	11
288	Statins and SARS-CoV-2 Infection: Results of a Population-Based Prospective Cohort Study of 469,749 Adults From 2 Canadian Provinces. Journal of the American Heart Association, 2021, 10, e022330.	1.6	11

#	ARTICLE	IF	CITATIONS
289	Comprehensive Quality-of-Life Outcomes With Invasive Versus Conservative Management of Chronic Coronary Disease in ISCHEMIA. <i>Circulation</i> , 2022, 145, 1294-1307.	1.6	11
290	Treatment of silent ischemia in unstable angina: A randomized comparison of sustained-release verapamil versus metoprolol. <i>Clinical Cardiology</i> , 1995, 18, 653-658.	0.7	10
291	Does 24-hour ST-segment resolution postfibrinolysis add prognostic value to a Q wave? An ASSENT 2 electrocardiographic substudy. <i>American Heart Journal</i> , 2003, 146, 640-645.	1.2	10
292	The impact of gender on the treatment and outcomes of patients with early reinfarction after fibrinolysis: insights from ASSENT-2†. <i>European Heart Journal</i> , 2003, 24, 1024-1034.	1.0	10
293	Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: Design and rationale of the SYNERGY Library. <i>American Heart Journal</i> , 2004, 148, 269-276.	1.2	10
294	Patient Age, Ethnicity, Medical History, and Risk Factor Profile, but Not Drug Insurance Coverage, Predict Successful Attainment of Glycemic Targets. <i>Diabetes Care</i> , 2010, 33, 2558-2560.	4.3	10
295	Prognostic utility of quantifying evolutionary ST-segment depression on early follow-up electrocardiogram in patients with non-ST-segment elevation acute coronary syndromes. <i>European Heart Journal</i> , 2010, 31, 958-966.	1.0	10
296	Temporal Trends and Referral Factors for Cardiac Rehabilitation Post-Acute Coronary Syndrome in Ontario: Insights From the Canadian Global Registry of Acute Coronary Events. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1604-1609.	0.8	10
297	Consistency of benefit from an early invasive strategy after fibrinolysis: a patient-level meta-analysis. <i>Heart</i> , 2015, 101, 1554-1561.	1.2	10
298	Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 225-233.	1.0	10
299	Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF. <i>International Journal of Cardiology</i> , 2018, 257, 78-83.	0.8	10
300	Long-term Follow-up of the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). <i>Canadian Journal of Cardiology</i> , 2018, 34, 736-743.	0.8	10
301	Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction: Insights from the ATLANTIC study. <i>American Heart Journal</i> , 2018, 196, 56-64.	1.2	10
302	Performance of acute coronary syndrome approaches in Brazil: a report from the BRACE (Brazilian Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Outcomes, 2020, 6, 284-292.	1.8	10
303	Rationale and design of the TAILOR-PCI digital study: Transitioning a randomized controlled trial to a digital registry. <i>American Heart Journal</i> , 2021, 232, 84-93.	1.2	10
304	Early invasive coronary angiography and acute ischaemic heart failure outcomes. <i>European Heart Journal</i> , 2021, 42, 3756-3766.	1.0	10
305	Lower is better: Implications of the Treating to New Targets (TNT) study for Canadian patients. <i>Canadian Journal of Cardiology</i> , 2006, 22, 835-839.	0.8	9
306	Impact of delayed presentation on management and outcome of non-ST-elevation acute coronary syndromes. <i>American Heart Journal</i> , 2008, 156, 262-268.	1.2	9

#	ARTICLE	IF	CITATIONS
307	Translational platelet research in patients with coronary artery disease: What are the major knowledge gaps?. <i>Thrombosis and Haemostasis</i> , 2012, 108, 12-20.	1.8	9
308	The Association Between Prior Use of Aspirin and/or Warfarin and the In-hospital Management and Outcomes in Patients Presenting With Acute Coronary Syndromes: Insights From the Global Registry of Acute Coronary Events (GRACE). <i>Canadian Journal of Cardiology</i> , 2012, 28, 48-53.	0.8	9
309	Comparison of the Efficacy of Pharmacoinvasive Management for ST-Segment Elevation Myocardial Infarction in Smokers Versus Non-Smokers (from the Trial of Routine Angioplasty and Stenting After Tj ETQq1 1 0.784314 rgBT /Over 2014, 114, 955-961.	0.7	9
310	Secondary Prevention Beyond Hospital Discharge for Acute Coronary Syndrome: Evidence-Based Recommendations. <i>Canadian Journal of Cardiology</i> , 2016, 32, S15-S34.	0.8	9
311	Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non-â€œST-Segment Elevation Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2017, 63, 1214-1226.	1.5	9
312	Longitudinal treatment patterns with ADP receptor inhibitors after myocardial infarction: Insights from the Canadian Observational AntiPlatelet sTudy. <i>International Journal of Cardiology</i> , 2017, 228, 459-464.	0.8	9
313	Optimizing screening and management of cardiovascular health in prostate cancer. <i>Canadian Urological Association Journal</i> , 2020, 14, E458-E464.	0.3	9
314	Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries. <i>International Journal of Cardiology</i> , 2020, 311, 7-14.	0.8	9
315	Meta-analysis Comparing Outcomes of Type 2 Myocardial Infarction and Type 1 Myocardial Infarction With a Focus on Dual Antiplatelet Therapy. <i>CJC Open</i> , 2020, 2, 118-128.	0.7	9
316	Does ambulatory monitoring contribute to exercise testing and myocardial perfusion scintigraphy in the prediction of the extent of coronary artery disease in stable angina?. <i>American Journal of Cardiology</i> , 1994, 73, 747-752.	0.7	8
317	Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial). <i>American Journal of Cardiology</i> , 2000, 86, 24-29.	0.7	8
318	Standards for the function of an academic 12-lead electrocardiographic core laboratory. <i>Journal of Electrocardiology</i> , 2001, 34, 41-47.	0.4	8
319	Short- and Long-Term Outcomes of Patients With Electrocardiographic Left Ventricular Hypertrophy After Fibrinolysis for Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2005, 96, 1050-1052.	0.7	8
320	Clinical implications of a next-day follow-up electrocardiogram in patients with non-ST elevation acute coronary syndromes. <i>American Heart Journal</i> , 2008, 156, 797-803.	1.2	8
321	Ischemic stroke: A cardiovascular risk equivalent? Lessons learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. <i>Canadian Journal of Cardiology</i> , 2008, 24, 705-708.	0.8	8
322	Pulmonary artery catheterization in patients with acute coronary syndromes. <i>American Heart Journal</i> , 2009, 158, 170-176.	1.2	8
323	Prognostic significance of electrocardiographic-determined left ventricular hypertrophy and associated ST-segment depression in patients with non-â€œST-elevation acute coronary syndromes. <i>American Heart Journal</i> , 2011, 161, 878-885.	1.2	8
324	Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events. <i>International Journal of Cardiology</i> , 2016, 218, 291-297.	0.8	8

#	ARTICLE	IF	CITATIONS
325	Use of Evidence-Based Therapy for Cardiovascular Risk Factors in Canadian Outpatients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2017, 120, 582-587.	0.7	8
326	Stress testing after percutaneous coronary interventions: a population-based study. <i>CMAJ Open</i> , 2017, 5, E417-E423.	1.1	8
327	Relation of High LipoproteinÂ(a) Concentrations to Platelet Reactivity in Individuals with and Without Coronary Artery Disease. <i>Advances in Therapy</i> , 2020, 37, 4568-4584.	1.3	8
328	Colchicine for Prevention of Atherothrombotic Events in Patients With Coronary Artery Disease: Review and Practical Approach for Clinicians. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1837-1845.	0.8	8
329	Enoxaparin and glycoprotein IIb/IIIa inhibition in nonâ€“ST-elevation acute coronary syndrome: Insights from the INTERACT trial. <i>American Heart Journal</i> , 2005, 149, S73-S80.	1.2	7
330	The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: The Enoxaparin in Nonâ€“Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy. <i>American Heart Journal</i> , 2006, 151, 791-797.	1.2	7
331	Quantitative troponin elevation does not provide incremental prognostic value beyond comprehensive risk stratification in patients with nonâ€“ST-segment elevation acute coronary syndromes. <i>American Heart Journal</i> , 2008, 155, 718-724.	1.2	7
332	Smoking status and antithrombin therapy in patients with nonâ€“ST-segment elevation acute coronary syndrome. <i>American Heart Journal</i> , 2008, 156, 177-184.	1.2	7
333	Efficacy of early invasive management post-fibrinolysis in men versus women with ST-elevation myocardial infarction: A subgroup analysis from Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). <i>American Heart Journal</i> , 2012, 164, 343-350.	1.2	7
334	Characteristics and Evidence-Based Management of Stable Coronary Artery Disease Patients in Canada Compared With the Rest of the World: Insights From the CLARIFY Registry. <i>Canadian Journal of Cardiology</i> , 2014, 30, 132-137.	0.8	7
335	Efficacy of Early Invasive Management After Fibrinolysis for ST-Segment Elevation Myocardial Infarction in Relation to Initial Troponin Status. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1221.e11-1221.e18.	0.8	7
336	Marital status and outcomes after myocardial infarction: Observations from the Canadian Observational Antiplatelet Study (COAPT). <i>Clinical Cardiology</i> , 2018, 41, 285-292.	0.7	7
337	Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial. <i>American Heart Journal</i> , 2019, 215, 106-113.	1.2	7
338	Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin. <i>Circulation</i> , 2019, 140, 1960-1963.	1.6	7
339	Short term outcome following acute phase switch among P2Y12 inhibitors in patients presenting with acute coronary syndrome treated with PCI: A systematic review and meta-analysis including 22,500 patients from 14 studies. <i>IJC Heart and Vasculature</i> , 2019, 22, 39-45.	0.6	7
340	Sex And Prognostic Significance of Self-Reported Frailty in Nonâ€“ST-Segment Elevation Acute Coronary Syndromes: Insights From the TRILOGY ACS Trial. <i>Canadian Journal of Cardiology</i> , 2019, 35, 430-437.	0.8	7
341	Cardiac Stress Testing After Coronary Revascularization. <i>American Journal of Cardiology</i> , 2020, 136, 9-14.	0.7	7
342	Improving the Design of Future PCI Trials for Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2020, 76, 435-450.	1.2	7

#	ARTICLE	IF	CITATIONS
343	Treatment Inertia in Patients With Familial Hypercholesterolemia. <i>Journal of the American Heart Association</i> , 2021, 10, e020126.	1.6	7
344	Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1842-1851.	0.8	7
345	Acute coronary thrombotic occlusion following exercise testing 6 weeks after percutaneous transluminal coronary angioplasty. <i>Catheterization and Cardiovascular Diagnosis</i> , 1992, 27, 40-44.	0.7	6
346	Low-molecular-weight heparins in ischemic heart disease. <i>Current Opinion in Cardiology</i> , 2004, 19, 309-316.	0.8	6
347	How many cardiovascular events can be prevented with optimal management of high-risk Canadians?. <i>Canadian Journal of Cardiology</i> , 2008, 24, 363-368.	0.8	6
348	Use of a Treatment Optimization Algorithm Involving Statin-Ezetimibe Combination Aids in Achievement of Guideline-Based Low-Density Lipoprotein Targets in Patients With Dyslipidemia at High Vascular Risk Guideline-Based Undertaking to Improve Dyslipidemia Management in Canada (GUIDANC). <i>Canadian Journal of Cardiology</i> , 2011, 27, 138-145.	0.8	6
349	Routine invasive management early after fibrinolysis: Relationship between baseline risk and treatment effects in a pooled patient-level analysis of 7 randomized controlled trials. <i>American Heart Journal</i> , 2014, 168, 757-765.e3.	1.2	6
350	Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial. <i>American Heart Journal</i> , 2018, 197, 1-8.	1.2	6
351	Electrocardiographic Findings in Patients With Acute Coronary Syndrome Presenting With Out-of-Hospital Cardiac Arrest. <i>American Journal of Cardiology</i> , 2018, 121, 294-300.	0.7	6
352	Pulse pressure in acute coronary syndromes: Comparative prognostic significance with systolic blood pressure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 309-317.	0.4	6
353	Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY-OUTCOMES. <i>Journal of the American College of Cardiology</i> , 2020, 75, 448-451.	1.2	6
354	Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome. <i>CJC Open</i> , 2020, 2, 402-415.	0.7	6
355	Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 549-559.	1.3	6
356	ST Resolution 1 Hour After Fibrinolysis for Prediction of Myocardial Infarct Size: Insights from ASSENT 3. <i>American Journal of Cardiology</i> , 2009, 103, 154-158.	0.7	5
357	Has the Clopidogrel and Metoprolol in Myocardial Infarction Trial (COMMIT) of early β -blocker use in acute coronary syndromes impacted on clinical practice in Canada? Insights from the Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , 2011, 161, 291-297.	1.2	5
358	Management of Risk Factors Among Ambulatory Patients at High Cardiovascular Risk in Canada: A Follow-up Study. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1586-1592.	0.8	5
359	Treatment and outcomes of non-ST elevation acute coronary syndromes in relation to burden of pre-existing vascular disease. <i>International Journal of Cardiology</i> , 2013, 168, 2720-2725.	0.8	5
360	Efficacy of an Early Invasive Strategy After Fibrinolysis in ST-Elevation Myocardial Infarction Relative to the Extent of Coronary Artery Disease. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1555-1561.	0.8	5

#	ARTICLE	IF	CITATIONS
361	Duration of dual antiplatelet therapy and associated outcomes following percutaneous coronary intervention for acute myocardial infarction: contemporary practice insights from the Canadian Observational Antiplatelet Study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2016, 3, qcw051.	1.8	5
362	Radial versus femoral access for percutaneous coronary intervention in ST-elevation myocardial infarction patients treated with fibrinolysis: Results from the randomized routine early invasive clinical trials. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 295-301.	0.3	5
363	A Practical Guide to the Use of Glucose-Lowering Agents With Cardiovascular Benefit or Proven Safety. <i>Canadian Journal of Cardiology</i> , 2017, 33, 940-942.	0.8	5
364	Non-vitamin K antagonist oral anticoagulant (NOAC) use and dosing in Canadian practice: Insights from the optimising pharmacotherapy in the management approach to lowering risk in atrial fibrillation (OPTIMAL AF) Programme. <i>International Journal of Clinical Practice</i> , 2020, 74, e13625.	0.8	5
365	Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial. <i>Diabetic Medicine</i> , 2021, 38, e14552.	1.2	5
366	Drug Adherence and Long-Term Outcomes in Non-Revascularized Patients Following Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2021, 152, 49-56.	0.7	5
367	Increasing Prevalence and Incidence of Atherosclerotic Cardiovascular Disease in Adult Patients in Ontario, Canada From 2002 to 2018. <i>CJC Open</i> , 2022, 4, 206-213.	0.7	5
368	Accuracy of Cardiovascular Trial Outcome Ascertainment and Treatment Effect Estimates from Routine Health Data: A Systematic Review and Meta-Analysis. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007903.	0.9	5
369	Non-alcoholic fatty liver disease and outcomes in persons with acute coronary syndromes: insights from the GRACE-ALT analysis. <i>Heart Asia</i> , 2012, 4, 137-140.	1.1	4
370	Relation Between Previous Angiotensin-Converting Enzyme Inhibitor Use and In-Hospital Outcomes in Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2012, 109, 332-336.	0.7	4
371	Management and Outcomes of Non-ST Elevation Acute Coronary Syndromes in Relation to Previous Use of Antianginal Therapies (from the Canadian Global Registry of Acute Coronary Events [GRACE]) <i>Tj ETQq1 1 0.784314 rgBT /Overbo</i> 112, 51-56.	0.7	4
372	Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes. <i>Coronary Artery Disease</i> , 2018, 29, 469-476.	0.3	4
373	Cost-Effectiveness of Different Durations of Dual-Antiplatelet Use After Percutaneous Coronary Intervention. <i>Canadian Journal of Cardiology</i> , 2018, 34, 31-37.	0.8	4
374	CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1350-1361.	0.8	4
375	Association Between Patient and Physician Sex and Physician-Estimated Stroke and Bleeding Risks in Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2019, 35, 160-168.	0.8	4
376	Pre-hospital administration of ticagrelor in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: A sub-analysis of the ATLANTIC trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E369-E377.	0.7	4
377	GOAL Canada: Physician Education and Support Can Improve Patient Management. <i>CJC Open</i> , 2020, 2, 49-54.	0.7	4
378	Short Duration vs Standard Duration of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents - A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials. <i>Journal of Invasive Cardiology</i> , 2016, 28, E203-E210.	0.4	4

#	ARTICLE	IF	CITATIONS
379	Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: Insights from the TREAT trial. <i>American Heart Journal</i> , 2022, 251, 1-12.	1.2	4
380	Risk factors and outcome of in-hospital ischemic stroke in patients with non-ST elevation acute coronary syndromes. <i>International Journal of Cardiology</i> , 2008, 129, 233-237.	0.8	3
381	The Impact of Postrandomization Crossover of Therapy in Acute Coronary Syndromes Care. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 211-219.	0.9	3
382	Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes. <i>Coronary Artery Disease</i> , 2013, 24, 321-327.	0.3	3
383	Clinical characteristics and outcomes of acute coronary syndrome patients with left anterior hemiblock. <i>Heart</i> , 2014, 100, 1456-1461.	1.2	3
384	Efficacy and Safety of a Routine Early Invasive Strategy in Relation to Time from Symptom Onset to Fibrinolysis (a Subgroup Analysis of TRANSFER-AMI). <i>American Journal of Cardiology</i> , 2015, 115, 1005-1012.	0.7	3
385	The relationship between the proportion of admitted high risk ACS patients and hospital delivery of evidence based care. <i>International Journal of Cardiology</i> , 2016, 222, 86-92.	0.8	3
386	Diabetes association with self-reported health, resource utilization, and prognosis post-myocardial infarction. <i>Clinical Cardiology</i> , 2020, 43, 1352-1361.	0.7	3
387	Does management of lipid lowering differ between specialists and primary care: Insights from GOAL Canada. <i>International Journal of Clinical Practice</i> , 2021, 75, e13861.	0.8	3
388	Contemporary use of guideline-based higher potency P2Y12 receptor inhibitor therapy in patients with moderate-to-high risk non-ST-segment elevation myocardial infarction: Results from the Canadian ACS reflective II cross-sectional study. <i>Clinical Cardiology</i> , 2021, 44, 839-847.	0.7	3
389	Use and outcomes of dual antiplatelet therapy for acute coronary syndrome in patients with chronic kidney disease: insights from the Canadian Observational Antiplatelet Study (COAPT). <i>Heart and Vessels</i> , 2022, 37, 1291-1298.	0.5	3
390	Are Canadian guidelines for cholesterol lowering in high-risk patients optimal?. <i>Canadian Journal of Cardiology</i> , 2005, 21, 85-90.	0.8	3
391	Bedtime Administration of Graded-Release Diltiazem in Patients with Inadequate BP Control. <i>American Journal of Cardiovascular Drugs</i> , 2006, 6, 393-400.	1.0	2
392	Comparison of Effectiveness of Enoxaparin Versus Unfractionated Heparin to Reduce Silent and Clinically Apparent Acute Myocardial Infarction in Patients Presenting With Non-ST-Segment Elevation Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2007, 99, 186-188.	0.7	2
393	Comparison of Site-Reported and Core Laboratory-Reported Creatine Kinase-MB Values in Non-ST-Segment Elevation Acute Coronary Syndrome (from the International Trial SYNERGY). <i>American Journal of Cardiology</i> , 2009, 104, 1330-1335.	0.7	2
394	Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 114-119.	1.0	2
395	Left Bundle Branch Block in Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1461-1463.	1.2	2
396	Prognostic significance of low QRS voltage on the admission electrocardiogram in acute coronary syndromes. <i>International Journal of Cardiology</i> , 2015, 201, 493.	0.8	2

#	ARTICLE	IF	CITATIONS
397	Prior bleeding, future bleeding and stroke risk with oral anticoagulation in atrial fibrillation: What new lessons can ARISTOTLE teach us?. American Heart Journal, 2016, 175, 168-171.	1.2	2
398	Adjunctive use of anticoagulants at the time of percutaneous coronary intervention in patients with an acute coronary syndrome treated with fondaparinux: a multinational retrospective review. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 214-220.	1.4	2
399	USE OF HIGH-INTENSITY STATIN THERAPY POST-ACUTE CORONARY SYNDROME IN THE ONGOING ODYSSEY OUTCOMES TRIAL OF ALIROCLUMAB, A PROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MONOCLONAL ANTIBODY, VERSUS PLACEBO: INTERIM BASELINE DATA. Journal of the American College of Cardiology, 2017, 69, 153.	1.2	2
400	Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis. American Heart Journal, 2017, 193, 46-54.	1.2	2
401	Clinical risk prediction models for the prognosis and management of acute coronary syndromes. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 222-228.	1.8	2
402	Use of antithrombotic therapy for secondary prevention in patients with stable atherosclerotic cardiovascular disease: Insights from the COordinated National Network to Engage Cardiologists in the antithrombotic Treatment of patients with CardioVascular Disease (CONNECTâ€CVD) study. International Journal of Clinical Practice, 2021, 75, e14597.	0.8	2
403	Prevalence of Cardiovascular Disease in a Population-Based Cohort of High-Cost Healthcare Services Users. CJC Open, 2022, 4, 180-188.	0.7	2
404	Cardiovascular risk factor management in patients with diabetes: Does management differ with disease duration?. Journal of Diabetes and Its Complications, 2021, 35, 107997.	1.2	2
405	Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry. Journal of Cardiology, 2021, , .	0.8	2
406	Preventing thrombosis: update of first-line therapy in the management of non-ST segment elevation acute coronary syndromes. Canadian Journal of Cardiology, 2002, 18, 1179-90.	0.8	2
407	Patient Onboarding and Engagement to Build a Digital Study After Enrollment in a Clinical Trial (TAILOR-PCI Digital Study): Intervention Study. JMIR Formative Research, 2022, 6, e34080.	0.7	2
408	Coronary angiography in Q-wave versus non-Q-wave acute myocardial infarction. American Journal of Cardiology, 1995, 76, 429-430.	0.7	1
409	Outcome of patients with acute coronary syndromes enrolled in clinical trials. Coronary Artery Disease, 2009, 20, 473-476.	0.3	1
410	Response to Letter Regarding Article, "Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From PLATO" Circulation, 2012, 126, .	1.6	1
411	PATIENTS WITH DIABETES AND PERIPHERAL ARTERIAL DISEASE: RESULTS FROM THE EXSCEL TRIAL. Journal of the American College of Cardiology, 2019, 73, 2040.	1.2	1
412	Glycemic Control and Cardiovascular Risk Factor Management in Adults With Type 2 Diabetes With and Without Chronic Kidney Disease Before Sodium-Glucose Cotransporter Protein 2 Inhibitors: Insights From the Diabetes Mellitus Status in Canada Survey. Canadian Journal of Diabetes, 2021, , .	0.4	1
413	An Association Between Cardiologist Billing Patterns, Health Care Use, and Outcomes in Cardiac Patients. CJC Open, 2021, 3, 758-768.	0.7	1
414	Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation: Findings from the CONNECT AF+PCI study. CJC Open, 2021, 3, 1419-1427.	0.7	1

#	ARTICLE	IF	CITATIONS
415	Provision of a DAPT Score to Cardiologists and Extension of Dual Antiplatelet Therapy Beyond 1 Year After ACS: Randomized Substudy of the Prospective Canadian ACS Reflective II Study. <i>CJC Open</i> , 2021, 3, 1463-1470.	0.7	1
416	Association of Cardiology Billing Amounts With Health Care Utilization and Clinical Outcomes in Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2021, 10, e020708.	1.6	1
417	The development of Partners for Health's integrated community pathway for postmyocardial infarction patients. <i>Canadian Journal of Cardiology</i> , 2003, 19, 231-5.	0.8	1
418	Enoxaparin and percutaneous coronary intervention: a Canadian perspective. <i>Canadian Journal of Cardiology</i> , 2005, 21, 501-7.	0.8	1
419	Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction. <i>Advances in Therapy</i> , 2022, 39, 1832-1843.	1.3	1
420	Objective risk assessment vs standard care for acute coronary syndromes—The Australian GRACE Risk tool Implementation Study (AGRIS): a process evaluation. <i>BMC Health Services Research</i> , 2022, 22, 380.	0.9	1
421	Access Denied? The Unintended Consequences of Pending Drug Pricing Rules. <i>Current Oncology</i> , 2022, 29, 2504-2508.	0.9	1
422	Sex-specific Differences in Clinical Outcomes After Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	1
423	Exertional sudden coronary death was associated with acute plaque rupture in men. <i>Evidence-based Cardiovascular Medicine</i> , 1999, 3, 61.	0.0	0
424	Enoxaparin Treatment in Unstable Coronary Artery Disease. <i>Chest</i> , 2002, 121, 666-667.	0.4	0
425	Are acute coronary syndromes risk models too complex? reply. <i>European Heart Journal</i> , 2007, 28, 2176-2177.	1.0	0
426	Title is missing!. <i>Canadian Journal of Cardiology</i> , 2007, 23, 398.	0.8	0
427	Does Enoxaparin Have Enough FINESSE to Replace Unfractionated Heparin in Primary Percutaneous Coronary Intervention?. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 213-214.	1.1	0
428	A Comparison of How Canadian Primary Care Physicians in Family Health Teams and Solo Physician Practices Manage Cardiometabolic Risk in Patients with Type 2 Diabetes Mellitus. <i>Canadian Journal of Diabetes</i> , 2012, 36, S39-S40.	0.4	0
429	Prognostic Implications of Prominent R Wave in Electrocardiographic Leads V1 or V2 in Patients With Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2014, 113, 1962-1967.	0.7	0
430	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial. <i>Journal of Clinical Lipidology</i> , 2019, 13, e54-e55.	0.6	0
431	USE OF EVIDENCE-BASED PREVENTIVE MEDICAL THERAPIES 1-3 YEARS POST-MYOCARDIAL INFARCTION IN THE PROSPECTIVE GLOBAL TIGRIS REGISTRY. <i>Journal of the American College of Cardiology</i> , 2019, 73, 169.	1.2	0
432	POST-ACUTE CORONARY SYNDROME PATIENTS WITH POLYVASCULAR DISEASE DERIVE LARGE ABSOLUTE BENEFIT FROM ALIROCUMAB: ODYSSEY OUTCOMES. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2034.	1.2	0

#	ARTICLE	IF	CITATIONS
433	Factors associated with actively working in the very long-term following acute coronary syndrome. Clinics, 2021, 76, e2553.	0.6	0
434	Drip and ship for acute ST-segment myocardial infarction. The pharmacoinvasive strategy for patients treated with fibrinolytic therapy. Polish Archives of Internal Medicine, 2009, 119, 726-730.	0.3	0
435	Long-Term Outcomes for Patients With Acute Coronary Syndrome and Nonvalvular Atrial Fibrillation. American Journal of Cardiology, 2022, , .	0.7	0
436	An early invasive strategy reduced the incidence of major cardiac events in patients with unstable coronary syndromes. ACP Journal Club, 2002, 136, 4.	0.1	0
437	Review: oral glycoprotein IIb/IIIa inhibitors increase mortality and myocardial infarction. ACP Journal Club, 2002, 137, 85.	0.1	0
438	Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Randomized Trial. American Journal of Medicine, 2022, , .	0.6	0
439	Associated factors and clinical outcomes in mechanical circulatory support use in patients undergoing high risk on-pump cardiac surgery: Insights from the LEVO-CTS trial. American Heart Journal, 2022, 248, 35-41.	1.2	0
440	Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial. Journal of the American Heart Association, 2021, 10, e023143.	1.6	0
441	Point of care CYP2C19 genotyping after percutaneous coronary intervention. Pharmacogenomics Journal, 2022, , .	0.9	0
442	Women with acute myocardial infarction had worse prognosis than men. ACP Journal Club, 1996, 125, 43.	0.1	0
443	Women had a worse prognosis than men after myocardial infarction. ACP Journal Club, 1999, 130, 46.	0.1	0
444	Abciximab and heparin given during coronary interventions reduced combined death, MI, and urgent revascularization. ACP Journal Club, 1999, 131, 40.	0.1	0
445	Abciximab was more effective than tirofiban in preventing ischemic events in patients having coronary stenting. ACP Journal Club, 2002, 136, 5.	0.1	0
446	Review: Oral glycoprotein IIb/IIIa inhibitors increase mortality and myocardial infarction. ACP Journal Club, 2002, 137, 85.	0.1	0